OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 430,000 clinicians using the startup’s free AI medical search tool regularly. That scale is paired with targeted pharmaceutical advertising that’s already pushed the company past a $100 million revenue run rate.
Virtual women’s health provider Midi Health has reached unicorn status after raising a $100 million Series D, with investors backing its insurance-covered, direct-to-consumer model. The company is positioning itself as a long-term, virtual “hospital without walls” designed to meet women’s health needs across midlife and beyond.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Function Health raised a $298 million Series B round, pushing its valuation into unicorn territory at $2.5 billion. The Austin-based startup offers subscribers access to more than 160 lab tests, as well as imaging.
Ambience Healthcare closed a $243 million Series C funding round, bringing its valuation to $1.25 billion. The startup, which offers an AI-powered platform for clinical documentation and coding, aims to reduce clinician burnout by automating time-consuming administrative tasks across a wide range of specialties.
Headway closed a $125 million Series C funding round. The round brings the New York-based startup’s valuation to $1 billion, reaching unicorn status. The company connects patients to in-network therapists and helps mental health providers avoid the massive administrative burden associated with taking insurance.
Digital health's investment slowdown is so severe that the fourth quarter of 2022 marked the lowest quarterly digital health funding total in the past five years, according to new report. Q4 was also the first quarter with no new unicorn births since 2018.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
There are currently 97 global digital health companies that are considered unicorns. But getting caught up with the idea of digital health unicorns isn’t very sustainable, according to Emilly Melton, managing partner at Threshold Ventures. Instead of focusing too much on their valuations, she recommended that startups simply focus on getting the capital they need in order to reach the next stage of inflection.
The company, which provides telemedicine and digital programs focused on maternal health, will use the funds raised to expand its services to new populations, including international patients and Medicaid members.
The health technology company's valuation skyrocketed to $1.3 billion following its latest funding round. It plans to use the new funds to launch Innovaccer Health Cloud, which will aggregate and normalize data from different systems and support the development of interoperable apps.
The newly crowned unicorn's insurance product enables members to shop for medical services and pay directly for care. The company raised $125 million in a recent funding round, boosting its valuation, which it will use to increase its footprint and launch new products.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Through the round led by OrbiMed, the Salt Lake City data analytics company has become a healthcare unicorn.
As of late October, healthcare's newest unicorn - Butterfly Network - has begun shipping its ultrasound-on-a-chip system that a senior executive believes will alter the field of ultrasound forever.
Here's how the Chicago startup that raised $500 million and accorded unicorn status stumbled amidst charges of deception, and what the task ahead is for its newly-appointed CEO from the advertising world.
In a statement, the cofounders of Outcome Health contended that the equity investors led by Goldman Sachs are misusing the court system,
Zenefits survived as a unicorn despite a major devaluation in 2016. Theranos did not. Human Longevity and Flatiron Health joined the exclusive club.